Forecasting the Impact of Medicare Part D Drug Negotiations

<p>David W. Johnson and Julie Murchinson forecast the regulatory and competitive industry implications of Medicare negotiating the prices for 10 drugs with pharmaceutical companies on the new episode of the 4sight Health Roundup podcast moderated by David Burda.</p> <p>David W. Johnson is CEO of 4sight Health.</p> <p>Julie Vaughan Murchinson is Partner of Transformation Capital and former CEO of Health Evolution.</p> <p>David Burda is News Editor and Columnist of 4sight Health.</p> <p>To bring your own revolutionary ideas to life, sponsor this podcast. Email <a href="mailto:info@4sighthealth.com">⁠⁠⁠⁠⁠⁠⁠⁠⁠info@4sighthealth.com⁠⁠⁠⁠⁠⁠⁠⁠⁠</a> for more.</p> <p>Listen on your podcast app or on the <a href="https://youtube.com/@4sighthealth">⁠⁠⁠⁠⁠⁠⁠⁠4sight Health YouTube Channel⁠⁠⁠⁠⁠⁠⁠⁠</a>.</p> <p>Subscribe on <a href="https://podcasts.apple.com/us/podcast/id1530045455">⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠</a>, <a href="https://open.spotify.com/show/0yAzDcHPHyRqxv3U1WA9Bd">⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠</a>, <a href="https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy8zMzQ3NTRlMC9wb2RjYXN0L3Jzcw==">⁠⁠⁠⁠⁠⁠⁠⁠Google Podcasts⁠⁠⁠⁠⁠⁠⁠⁠</a> and <a href="https://youtube.com/@4sighthealth">⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠</a>.</p>